---Select--- Sort by Relevance Sort by Date(descending) Sort by Date(ascending)
Astellas Pharma Europe BV, of Meppel, The Netherlands, a subsidiary of Astellas
Pharma Inc ., reported the Dutch Medicines Evaluation Board granted marketing authorization for Vesomni (solifenacin + tamsulosin) in the Netherlands
BioWorld Today |
Friday, May 24, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
---Select--- Sort by Relevance Sort by Date(descending) Sort by Date(ascending)
Astellas Pharma Europe BV, of Meppel, The Netherlands, a subsidiary of Astellas Pharma Inc., reported the Dutch Medicines Evaluation Board granted marketing authorization for Vesomni (solifenacin + tamsulosin) in the Netherlands